Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: Role of aminoguanidine
- 1 January 2004
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 18 (2) , 69-77
Abstract
Doxorubicin (DOX) is a potent antitumor antibiotic drug known to cause severe cardiac toxicity. Moreover, its adverse effects were found to be extended to the cerebral tissue. Several mechanisms for this toxicity have been ascribed. Currently, one of the most accepted mechanisms is through free radicals; however, the exact role of nitric oxide (NO) is still unclear. Accordingly, a NO‐synthase inhibitor with some antioxidant property, aminoguanidine (AG), was selected to examine its potential protective effect against DOX‐induced toxicity. Male Wistar albino rats (150–200 g) were allocated into a normal control group, DOX‐induced toxicity group, and DOX + AG‐treated group. DOX was injected i.p. at a dose of 10 mg/kg divided into four equal injections over a period of 2 weeks. AG was injected i.p. at a dose of 100 mg/kg 1 h before each DOX injection. The animals were sacrificed 24 h after the last DOX injection and the following parameters were measured: serum lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) activities, cardiac and cerebral contents of malondialdehyde (MDA), conjugated diene (CD), glutathione (GSH), NO, and cytosolic calcium, as well as superoxide dismutase (SOD) and glutathione peroxidase (GSHPX) activities. Cardiotoxicity was manifested by a marked increase in serum LDH and CPK in addition to the sharp increase in MDA reaching eightfolds the basal level. This was accompanied by significant increase in CD, NO, cytosolic calcium, SOD, and GSHPX content/activity by 69, 85, 76, 125, and 41% respectively as compared to normal control. On the other hand, GSH was significantly depressed. In brain, only significant increase in MDA and GSHPX and decrease in GSH were obtained but to a lesser extent than the cardiac tissue. AG treatment failed to prevent the excessive release of cardiac enzymes; however, it alleviated the adverse effects of DOX in heart. AG administration resulted in marked decrease in the elevated levels of MDA, NO, SOD, and GSHPX, however, MDA level was still pathological. The altered parameters in brain were restored by AG. It is concluded that, AG could not provide complete protection against DOX‐induced toxicity. Therefore, it is recommended that, maintenance of the endogenous antioxidant, GSH, and regulation of calcium homeostasis must be considered, rather than NO formation, to guard against DOX‐induced toxicity. © 2004 Wiley Periodicals, Inc. J Biochem Mol Toxicol 18:69–77, 2004; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20013Keywords
This publication has 48 references indexed in Scilit:
- Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac DysfunctionCirculation, 2003
- Neuroprotective effects of bcl‐2 overexpression in hippocampal cultures: interactions with pathways of oxidative damageJournal of Neurochemistry, 2002
- Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastomaToxicology Letters, 2002
- Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced CardiomyopathyBasic & Clinical Pharmacology & Toxicology, 2001
- Nitric Oxide Contributes to Adriamycin's Antitumor EffectJournal of Surgical Research, 1997
- Glucocorticoids Increase the Accumulation of Reactive Oxygen Species and Enhance Adriamycin-Induced Toxicity in Neuronal CultureExperimental Neurology, 1996
- Increase in Brain Nitric Oxide Synthase Activity in Daunorubicin‐treated RatsBasic & Clinical Pharmacology & Toxicology, 1996
- Vitamin A Inhibits Doxorubicin-Induced Membrane Lipid Peroxidation in Rat Tissues in VivoArchives of Biochemistry and Biophysics, 1993
- DNA damage fey anthracyclines and their copper(II) complexesEuropean Journal of Pharmacology, 1990
- Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administrationAmerican Heart Journal, 1986